Novartis AGNVSNYSE
Loading
Year-over-year research & development expense growth
Percentile
P36
Within normal range
vs 5Y Ago
-0.4x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -3.64% |
| Q3 2025 | 7.96% |
| Q2 2025 | 15.26% |
| Q1 2025 | -16.75% |
| Q4 2024 | 18.81% |
| Q3 2024 | 1.06% |
| Q2 2024 | -2.23% |
| Q1 2024 | -5.69% |
| Q4 2023 | -34.60% |
| Q3 2023 | 70.36% |
| Q2 2023 | -10.52% |
| Q1 2023 | 5.45% |
| Q4 2022 | -3.93% |
| Q3 2022 | 1.76% |
| Q2 2022 | 7.67% |
| Q1 2022 | -3.69% |
| Q4 2021 | 1.22% |
| Q3 2021 | -0.83% |
| Q2 2021 | 2.08% |
| Q1 2021 | 0.77% |
| Q4 2020 | 8.71% |
| Q3 2020 | -12.09% |
| Q2 2020 | 18.50% |
| Q1 2020 | -27.80% |
| Q4 2019 | 29.74% |
| Q3 2019 | 7.22% |
| Q2 2019 | -10.79% |
| Q1 2019 | -4.17% |
| Q4 2018 | 11.74% |
| Q3 2018 | 0.99% |
| Q2 2018 | 7.27% |
| Q1 2018 | -20.78% |
| Q4 2017 | 11.75% |
| Q3 2017 | 8.58% |
| Q2 2017 | -4.93% |
| Q1 2017 | -16.06% |
| Q4 2016 | 16.19% |
| Q3 2016 | 1.55% |
| Q2 2016 | 7.30% |
| Q1 2016 | -17.44% |